This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fine, H. A. Articles by Yung, W. K. A. Search for Related Content PubMed PubMed Citation Articles by Fine, H. A. Articles by Yung, W. K. A.

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

From the Center for Neuro-Oncology, Dana-Farber Cancer Institute, and Departments of Neurology, Surgery, and Radiation Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; Department of Neuro-Oncology, M.D. Anderson Cancer Center, and National Central Nervous System Consortium, Houston, TX; and Cancer Treatment and Evaluation Program, Investigational Drug Branch, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda MD.

Address reprint requests to Howard A. Fine, MD, Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Rm 12W253, 10 Center Dr, Bethesda, MD 20892-2440; email hf32p{at}nih.gov

ABSTRACT

PURPOSE: Little progress has been made in the treatment of adult high-grade gliomas over the last two decades, thus necessitating a search for novel therapeutic strategies. Malignant gliomas are vascular or angiogenic tumors, which leads to the supposition that angiogenesis inhibition may represent a potentially promising strategy in the treatment of these tumors. We present the results of a phase II trial of thalidomide, a putative inhibitor of angiogenesis, in the treatment of adults with previously irradiated, recurrent high-grade gliomas.

PATIENTS AND METHODS: Patients with a histologic diagnosis of anaplastic mixed glioma, anaplastic astrocytoma, or glioblastoma multiforme who had radiographic demonstration of tumor progression after standard external-beam radiotherapy with or without chemotherapy were eligible. Patients were initially treated with thalidomide 800 mg/d with increases in dose by 200 mg/d every 2 weeks until a final daily dose of 1,200 mg was achieved. Patients were evaluated every 8 weeks for response by both clinical and radiographic criteria.

RESULTS: A total of 39 patients were accrued, with 36 patients being assessable for both toxicity and response. Thalidomide was well tolerated, with constipation and sedation being the major toxicities. One patient developed a grade 2 peripheral neuropathy after treatment with thalidomide for nearly a year. There were two objective radiographic partial responses (6%), two minor responses (6%), and 12 patients with stable disease (33%). Eight patients were alive more than 1 year after starting thalidomide, although almost all with tumor progression. Changes in serum levels of basic fibroblastic growth factor (bFGF) were correlated with time to tumor progression and overall survival.

CONCLUSION: Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas. Future studies will better define the usefulness of thalidomide in newly diagnosed patients with malignant gliomas and in combination with radiotherapy and chemotherapy. Additionally, studies will be needed to confirm the potential utility of changes in serum bFGF as a marker of antiangiogenic activity and/or glioma growth.

This article has been cited by other articles:

				V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme Neuro-oncol, April 1, 2008; 10(2): 216 - 222. [Abstract] [Full Text] [PDF]

				S. Kesari, D. Schiff, J. W. Henson, A. Muzikansky, D. C. Gigas, L. Doherty, T. T. Batchelor, J. A. Longtine, K. L. Ligon, S. Weaver, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults Neuro-oncol, January 1, 2008; 10(3): 300 - 308. [Abstract] [Full Text] [PDF]

				H. A. Fine, L. Kim, P. S. Albert, J. P. Duic, H. Ma, W. Zhang, T. Tohnya, W. D. Figg, and C. Royce A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors Clin. Cancer Res., December 1, 2007; 13(23): 7101 - 7106. [Abstract] [Full Text] [PDF]

				S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro-oncol, July 1, 2007; 9(3): 354 - 363. [Abstract] [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res., February 15, 2007; 13(4): 1253 - 1259. [Abstract] [Full Text] [PDF]

				N. A. Butowski, P. K. Sneed, and S. M. Chang Diagnosis and Treatment of Recurrent High-Grade Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1273 - 1280. [Abstract] [Full Text] [PDF]

				S. R. Burzynski, T. J. Janicki, R. A. Weaver, and B. Burzynski Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma. Integr Cancer Ther, March 1, 2006; 5(1): 40 - 47. [Abstract] [PDF]

				P.-K. Li, B. Pandit, D. L. Sackett, Z. Hu, J. Zink, J. Zhi, D. Freeman, R. W. Robey, K. Werbovetz, A. Lewis, et al. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol. Cancer Ther., February 1, 2006; 5(2): 450 - 456. [Abstract] [Full Text] [PDF]

				D. A. Reardon and P. Y. Wen Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, February 1, 2006; 11(2): 152 - 164. [Abstract] [Full Text] [PDF]

				J. D. Schwartz, M. Sung, M. Schwartz, D. Lehrer, J. Mandeli, L. Liebes, A. Goldenberg, and M. Volm Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-{alpha}2a upon Progression Oncologist, October 1, 2005; 10(9): 718 - 727. [Abstract] [Full Text] [PDF]

				C. J. Langer and M. P. Mehta Current Management of Brain Metastases, With a Focus on Systemic Options J. Clin. Oncol., September 1, 2005; 23(25): 6207 - 6219. [Abstract] [Full Text] [PDF]

				H M. Prince, L. Mileshkin, A. Roberts, V. Ganju, C. Underhill, J. Catalano, R. Bell, J. F. Seymour, D. Westerman, P. J. Simmons, et al. A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma Clin. Cancer Res., August 1, 2005; 11(15): 5504 - 5514. [Abstract] [Full Text] [PDF]

				S. Brem, S. A. Grossman, K. A. Carson, P. New, S. Phuphanich, J. B. Alavi, T. Mikkelsen, J. D. Fisher, and for the New Approaches to Brain Tumor Therapy CNS Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma Neuro-oncol, July 1, 2005; 7(3): 246 - 253. [Abstract] [PDF]

				C. Hsu, C.-N. Chen, L.-T. Chen, C.-Y. Wu, F.-J. Hsieh, and A.-L. Cheng Effect of Thalidomide in Hepatocellular Carcinoma: Assessment with Power Doppler US and Analysis of Circulating Angiogenic Factors Radiology, May 1, 2005; 235(2): 509 - 516. [Abstract] [Full Text] [PDF]

				M. E Gordinier and D. S Dizon Dyspnea During Thalidomide Treatment for Advanced Ovarian Cancer Ann. Pharmacother., May 1, 2005; 39(5): 962 - 965. [Abstract] [Full Text] [PDF]

				E. W. B. Jeffes, J. G. Zhang, N. Hoa, A. Petkar, C. Delgado, S. Chong, A. Obenaus, R. Sanchez, S. Khalaghizadeh, T. Khomenko, et al. Antiangiogenic Drugs Synergize with a Membrane Macrophage Colony-Stimulating Factor-Based Tumor Vaccine to Therapeutically Treat Rats with an Established Malignant Intracranial Glioma J. Immunol., March 1, 2005; 174(5): 2533 - 2543. [Abstract] [Full Text] [PDF]

				G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions J. Clin. Oncol., February 20, 2005; 23(6): 1295 - 1311. [Abstract] [Full Text] [PDF]

				F. Chung, J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, M. Tingle, and L.-M. Ching Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients Clin. Cancer Res., September 1, 2004; 10(17): 5949 - 5956. [Abstract] [Full Text] [PDF]

				V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos Thalidomide in cancer medicine Ann. Onc., August 1, 2004; 15(8): 1151 - 1160. [Abstract] [Full Text] [PDF]

				S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF]

				S. S. W. Ng, G. R. MacPherson, M. Gutschow, K. Eger, and W. D. Figg Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice Clin. Cancer Res., June 15, 2004; 10(12): 4192 - 4197. [Abstract] [Full Text] [PDF]

				J. K. Pueschel Integrative Tumor Board: Glioblastoma Multiforme: Neurooncology Integr Cancer Ther, June 1, 2004; 3(2): 151 - 152. [PDF]

				L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age Blood, July 1, 2003; 102(1): 69 - 77. [Abstract] [Full Text] [PDF]

				S. S. W. Ng, M. Gutschow, M. Weiss, S. Hauschildt, U. Teubert, T. K. Hecker, F. A. Luzzio, E. A. Kruger, K. Eger, and W. D. Figg Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues Cancer Res., June 15, 2003; 63(12): 3189 - 3194. [Abstract] [Full Text] [PDF]

				H. A. Fine, P. Y. Wen, E. A. Maher, E. Viscosi, T. Batchelor, N. Lakhani, W. D. Figg, B. W. Purow, and C. B. Borkowf Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas J. Clin. Oncol., June 15, 2003; 21(12): 2299 - 2304. [Abstract] [Full Text] [PDF]

				J. Lu, B. D. Palmer, P. Kestell, P. Browett, B. C. Baguley, G. Muller, and L.-M. Ching Thalidomide Metabolites in Mice and Patients with Multiple Myeloma Clin. Cancer Res., May 1, 2003; 9(5): 1680 - 1688. [Abstract] [Full Text] [PDF]

				A. Gupta, B.H. Cohen, P. Ruggieri, R.J. Packer, and P.C. Phillips Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 Neurology, January 14, 2003; 60(1): 130 - 132. [Abstract] [Full Text] [PDF]

				F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]

				S. Majumdar, B. Lamothe, and B. B. Aggarwal Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester J. Immunol., March 15, 2002; 168(6): 2644 - 2651. [Abstract] [Full Text] [PDF]

				C.S. Brock and S.M. Lee Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer Eur. Respir. J., March 1, 2002; 19(3): 557 - 570. [Abstract] [Full Text] [PDF]

				M. B. Steins, T. Padro, R. Bieker, S. Ruiz, M. Kropff, J. Kienast, T. Kessler, T. Buechner, W. E. Berdel, and R. M. Mesters Efficacy and safety of thalidomide in patients with acute myeloid leukemia Blood, February 1, 2002; 99(3): 834 - 839. [Abstract] [Full Text] [PDF]

				R. S. Kerbel Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51. [Full Text] [PDF]

				K. Neben, T. Moehler, G. Egerer, A. Kraemer, J. Hillengass, A. Benner, A. D. Ho, and H. Goldschmidt High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma Clin. Cancer Res., September 1, 2001; 7(9): 2675 - 2681. [Abstract] [Full Text] [PDF]

				S. A. Grossman, S. Phuphanich, G. Lesser, J. Rozental, L. B. Grochow, J. Fisher, and S. Piantadosi Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas J. Clin. Oncol., July 1, 2001; 19(13): 3260 - 3266. [Abstract] [Full Text] [PDF]

				E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho Malignant glioma: genetics and biology of a grave matter Genes & Dev., June 1, 2001; 15(11): 1311 - 1333. [Full Text] [PDF]

				L. M. DeAngelis Brain Tumors N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123. [Full Text] [PDF]

				F. A. Greco, J. D. Hainsworth, N. Levitan, and A. Dowlati Paclitaxel for limited-stage small-cell lung cancer. J. Clin. Oncol., October 1, 2000; 18(19): 3453 - 3454. [Full Text] [PDF]